{"url_path":"/sec/lmed/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 Controls and****Procedures**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1477960/0001477932-26-003348-index.html","accession_number":"0001477932-26-003348","cik":"0001477960","ticker":"LMED","issuer_name":"LataMed AI Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477960/0001477932-26-003348-index.html","primary_entity_key":"0001477960","primary_entity_name":"LataMed AI Corp."},"word_count":176,"has_tables":true,"body_markdown":"**Item 4. Controls and****Procedures**\n\n  \n\n**Evaluation of Disclosure Controls and Procedures**\n\n \n\nUnder the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, as of March 31, 2026. Based on this evaluation, management concluded that our financial disclosure controls and procedures were not effective so as to timely record, process, summarize and report financial information required to be included on our SEC reports due to the Company’s limited internal resources and lack of ability to have multiple levels of transaction review. However, as a result of our evaluation and review process, management believes that the financial statements and other information presented herewith are materially correct.\n\n  \n\n**Change in Internal Control Over Financial Reporting**\n\n \n\nThe Company has not made any change in our internal control over financial reporting during the period ended March 31, 2026.\n\n \n\n \n\n16\n\n*Table of Contents*\n\n  \n\n**PART II. OTHER INFORMATION**"}